Introduction {#s001}
============

F[rench gynecologist Raoul Palmer]{.smallcaps} was the first to use laparoscopy for minor surgical interventions in the late 1950s; in 1989, Reich described the first laparoscopic hysterectomy.^[@B1]^ Laparoscopy offers many advantages,^[@B2]^ including less pain, faster recovery, shorter hospital stay, and quicker return to normal activities.

Radical hysterectomy is conventionally used to surgically manage early-stage cervical carcinoma.^[@B3]^ The most commonly used definition was proposed by Piver et al.^[@B4]^ in 1974, combining with a pelvic with or without para-aortic lymphadenectomy.^[@B5]^ Abdominal radical hysterectomy (ARH) is associated with postoperative morbidities such as bladder dysfunction, colorectal motility disorders, and longer hospital stay. Because of advances in minimally invasive surgery, laparoscopic radical hysterectomy (LRH) is now routinely performed worldwide. The laparoscopic approach has fewer operative complications and less morbidity than the abdominal procedure without lowering the cure rate.^[@B6]^

More recently, LRH has been increasingly used for operable cervical carcinoma. Although several studies comparing these two techniques have been reported, whether the benefits of LRH are greater remains uncertain because most are small series with conflicting results.^[@B7],[@B8]^ The prognostic results were not reviewed before. We decided to rigorously test this belief to evaluate the efficiency, safety, and prognostic results of LRH compared with ARH.

Materials and Methods {#s002}
=====================

Literature search, inclusion, data extraction, and outcomes of interest {#s003}
-----------------------------------------------------------------------

A prospective protocol was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis^[@B9]^ and Meta-analysis of Observational Studies in Epidemiology recommendations.^[@B10]^ All related studies published through April 1, 2015 were screened by systematic searches in PubMed, EMBASE, and the Cochrane Library. Medical subject heading terms were identified, and their combinations were searched in \[Title/Abstract\]:laparoscopy/laparoendoscopy/peritoneoscopy/abdominoscopy/transabdominal/laparotomic/open/traditional/abdominal, radical hysterectomy, and uterine cervical neoplasms. The Related Articles function was also used, and reference lists of all retrieved studies, review articles, and conference abstracts were also manually searched. When reports published data on the same population, the most recent report was used.

All available randomized controlled trial (RCTs), nonrandomized controlled designs, and retrospective comparative studies (cohort or case--control studies) were included. Patients had biopsy-proven cervical cancer and had a radical hysterectomy performed. Editorials, letters to the editor, review articles, case reports, and animal experimental studies were excluded.

The primary outcomes were 5-year disease-free survival (DFS), 5-year overall survival (OS), and recurrence rate (RR). The secondary outcomes included the safety parameters, the efficiency parameters, and others. The safety parameters were intraoperative bowel or urinary injury, intraoperative, perioperative, and postoperative complications, and postoperative bladder or bowel recovery days. The efficiency parameters were number of pelvic and para-aortic lymph nodes removed. Other parameters were the operative time, estimated blood loss (EBL), and length of stay (LOS). If sufficient data were available, perioperative complications were subdivided into intraoperative complications and postoperative complications within 30 days of surgery.

Additionally, because prognostic factors are important for determining the survival rate, the characteristics of grade, histology, lymphovascular space invasion, positive lymph node rate, positive parametrial margin rate, and positive vaginal margin rate between the two groups were analyzed.

Quality assessment and statistical analysis {#s004}
-------------------------------------------

The quality assessment and statistical analysis were done by the criteria of the Centre for Evidence-Based Medicine in Oxford, United Kingdom, based on the level of evidence provided.^[@B11]^ For RCTs, the Cochrane risk of bias tool was used to assess methodological quality. For retrospective studies, the modified Newcastle--Ottawa Scale,^[@B12],[@B13]^ comprising three factors (patient selection, study group comparability, and outcome assessment), was used in methodological quality assessment. We allocated a score from 0 to 9 (allocated as stars) to each study (except RCTs) based on their methodological quality assessment results. RCTs and observational studies with six or more stars were considered to be of high quality.

All meta-analyses were performed using Review Manager version 5.0 software (Cochrane Collaboration, Oxford). Continuous variables were analyzed using the weighted mean difference (WMD), dichotomous variables were analyzed using odds ratios (ORs), and survival variables were compared using hazard ratios (HRs). We reported the results with 95% confidence intervals (CIs). We calculated the standard deviations of studies that presented continuous data as the means and ranges using the technique described by Hozo et al.^[@B14]^ Statistical heterogeneity between studies was assessed using a chi-squared test, with significance set at *P* \< .10, as well as using the *I*^2^ statistic. A random-effects model was used if heterogeneity existed between studies; otherwise, a fixed-effects model was used. Subgroup analyses were performed to define safety and efficiency of the LRH approach. We also performed sensitivity analyses for high-quality studies and used funnel plots to screen for potential publication bias.

Results {#s005}
=======

Characteristics of studies {#s006}
--------------------------

Twenty-two studies including 2922 cases (1230 LRH cases and 1692 ARH cases) met the inclusion criteria. Twenty-one publications were full-text articles,^[@B15]^ and one publication was an abstract.^[@B37]^ The references listed for these studies and review articles were also examined, but no further studies were included.

[Table 1](#T1){ref-type="table"} shows the characteristics of included studies, which included 1 small RCT^[@B15]^ (Level of Evidence 2b), 15 retrospective studies,^[@B16],[@B37]^ and 6 prospective studies^[@B30],[@B35],[@B36]^ comparing a contemporary series of patients (Level of Evidence 3b). Five studies examined cases with Stage IB1 or below disease.^[@B15],[@B16],[@B26],[@B32],[@B37]^ Sixteen studies included cases with locally advanced Stage IB2--IIB disease,^[@B17],[@B22],[@B27],[@B34]^ and only two studies^[@B31],[@B33]^ included cases with Stage IIB disease. One study defined stage IB1 as a tumor size of less than 2 cm.^[@B32]^ One study included cervical cancer tumors diagnosed as FIGO Stage IB--IIA, with a tumor diameter of 3 cm or greater.^[@B18]^ Patients in one study were treated with neoadjuvant chemotherapy prior to radical surgery.^[@B33]^ Outcomes are shown in [Table 2](#T2){ref-type="table"}.

###### 

[Characteristics of Included Studies]{.smallcaps}

                                                      *Number of patients*                                                  
  ---------------------------- ---- ----- ----------- ---------------------- ----- ---------------------- ----------------- -----
  Bogani et al.^[@B31]^        3b   RP    IA2--IIB    65                     65    1, 3--6, 8, 9          58.8/106.2        7
  Campos et al.^[@B15]^        2b   RCT   IA2--IB1    16                     14    1, 2, 4, 5, 7, 8, 10   5 years/5 years   RCT
  Diaz-Feijoo et al.^[@B22]^   3b   R     IA2--IIA    20                     30    4, 5, 8                22.5/35           7
  Ditto et al.^[@B32]^         3b   RP    IA2--IB1    60                     60    1, 3--6, 8             31/48.7           7
  Frumovitz et al.^[@B17]^     3b   R     IA1--IB2    35                     44    1, 3--5                7.2/15.2          7
  Ghezzi et al.^[@B33]^        3b   RP    IB2--IIB    68                     273   1, 3--5                35/41             7
  Ghezzi et al.^[@B23]^        3b   R     IA2--IIA    50                     48    1--6, 8                58/10             6
  Kong et al.^[@B18]^          3b   R     IB--IIA     40                     48    1, 3--5, 7, 8          28/58             7
  Lee et al.^[@B24]^           3b   R     I--IIA      8                      16    1, 3--5, 8, 10         78/75             5
  Li et al.^[@B25]^            3b   R     IB--IIA     90                     35    1, 3, 6, 9, 10         26/26             4
  Lim et al.^[@B30]^           3b   RP    IA--IB2     18                     30    1--5, 9                37.3/23 weeks     7
  Malzoni et al.^[@B26]^       3b   R     IA1--IB1    65                     62    1, 3--5, 9             52.5/71.5         6
  Nam et al.^[@B35]^           3b   RP    IA2--IIA    263                    263   1, 4, 5, 9             92/63             7
  Park et al.^[@B19]^          3b   R     IA2--IIA2   99                     159   1--8                   49/57             3
  Park et al.^[@B27]^          3b   R     IA2--IIA2   54                     112   1--5, 7, 8             49.2/60.9         3
  Park et al.^[@B28]^          3b   R     IB2, IIA2   115                    188   1--5, 7--9             30/30             6
  Sobiczewski et al.^[@B20]^   3b   R     IA--IIA     22                     58    1, 4--6, 9             26/47             4
  Stanciu et al.^[@B37]^       3b   R     IA2--IB1    31                     45    NA                     NA                4
  Taylor et al.^[@B16]^        3b   R     IA2--IB1    9                      18    1, 3--5                35.3/35.1         6
  Toptas and Simsek^[@B21]^    3b   R     IA2--IB1    22                     46    1, 5, 9                42.5/43.5         5
  Uccella et al.^[@B29]^       3b   R     IA2--IIA    50                     48    1--4, 8                NA                7
  Zakashansky et al.^[@B36]^   3b   RP    IA1--IIA    30                     30    1, 4--6, 9             20/40             5

Matching: 1 = age; 2 = parity; 3 = body mass index; 4 = stage; 5 = histology; 6 = grade; 7 = American Society of Anesthesiologists score; 8 = previous abdominal surgery history; 9 = tumor size; 10 = single surgeon.

Mean or median.

ARH, abdominal radical hysterectomy; LRH, laparoscopic radical hysterectomy; NA, data not available; R, retrospective; RP, retrospective design, prospective data collection; RCT, randomized controlled trial.

###### 

[Results of Meta-analysis Comparison of Laparoscopic Radical Hysterectomy and Abdominal Radical Hysterectomy]{.smallcaps}

                                                          *Number of patients*                                       *Study heterogeneity*                      
  -------------------------------------------------- ---- ---------------------- ------ ---------------------------- ----------------------- -------- ---- ---- --------------
  Primary outcomes                                                                                                                                              
   5-year DFS^[b](#tf5){ref-type="table-fn"}^        10   791                    1031   0.01 (−0.10, 0.11)           .91                     4.78     9    0    .85
   5-year OS^[b](#tf5){ref-type="table-fn"}^         6    656                    847    −0.02 (−0.14, 0.10)          .73                     4.28     5    0    .51
   Recurrence rate^[b](#tf5){ref-type="table-fn"}^   13   924                    1350   0.82 (0.61, 1.11)            .20                     3.37     12   0    .99
  Secondary outcomes                                                                                                                                            
   Intraoperative bowel-urinary injury               17   1083                   1282   1.50 (0.99, 2.26)            .06                     6.79     16   0    .98
   Perioperative complication                        4    315                    555    0.56 (0.36, 0.90)            **.02**                 2.50     3    0    .47
   Postoperative complication                        18   1078                   1451   0.75 (0.62, 0.91)            **.003**                40.31    16   60   **.0007**
   Intraoperative complication                       10   523                    661    1.48 (0.75, 2.91)            .25                     8.31     9    0    .50
   Bladder recovery (days)                           3    61                     119    −2.48 (−5.16, 0.19)          .07                     17.46    2    89   **.0002**
   Anorectal recovery (days)                         4    104                    123    −0.80 (−1.16, −0.44)         **\<.00001**            4.65     2    57   .1
   Pelvic LNs removed                                16   813                    1220   −1.44 (−4.14, 1.27)          .3                      247.44   15   94   **\<.00001**
   Para-aortic LNs removed                           2    73                     78     −1.79 (−6.39, 2.82)          .45                     18.41    1    95   **\<.0001**
   Operation time (minutes)                          17   841                    1383   18.76 (2.13, 35.39)          **.03**                 184.15   16   91   **\<.00001**
   Length of stay (days)                             16   1054                   1437   −4.36 (−5.38, −3.34)         **\<.00001**            141.26   15   89   **\<.00001**
   Blood loss (mL)                                   17   1089                   1481   −193.61 (−236.80, −150.43)   **\<.00001**            80.44    16   80   **\<.00001**

Statistically significant results are shown in bold.

Prognostic factors were not significantly different.

ARH, abdominal radical hysterectomy; CI, confidence interval; *df*, degrees of freedom; DFS, disease-free survival; LN, lymph node; LRH, laparoscopic radical hysterectomy; OS, overall survival; WMD/OR, weighted mean difference/odds ratio.

Methodological quality of the included studies {#s007}
----------------------------------------------

The quality of the included studies was generally low. Only one RCT was included. Matching criteria between the groups varied, and little matching information was identified from the conference abstracts. Twenty-one studies mentioned the length of follow-up time, except for one abstract lacking the full article^[@B37]^; the follow-up time varied in these studies.

Primary outcomes {#s008}
----------------

Among these studies, prognostic factors showed no significant difference, including Stage IIB or above (only two studies included Stage IIB or above^[@B23],[@B31]^ and showed no differences; others included cases below Stage IIB), Grade G3 (OR = 1.44; 95% CI, 0.70, 2.96; *P* = .32), non--squamous cancer histology (OR = 0.98; 95% CI, 0.78, 1.23; *P* = .84), positive lymph node rate (OR = 1.08; 95% CI, 0.83, 1.41; *P* = .57), positive lymphovascular space invasion (OR = 1.26; 95% CI, 0.68, 2.33; *P* = .47), tumor size ≥4 cm (OR = 1.27; 95% CI, 0.62, 2.62; *P* = .52), positive parametrial margin rate (OR = 1.12; 95% CI, 0.71, 1.78; *P* = .62), and positive vaginal margin rate (OR = 2.79; 95% CI, 0.88, 8.82; *P* = .08).

Under the balanced prognostic factors, the total effect of DFS and OS showed no difference (HR = −0.01; 95% CI, −0.08, 0.07; *P* = .88). Ten studies^[@B18],[@B24],[@B26],[@B31],[@B32],[@B35]^ including 1822 patients assessed DFS, and six studies assessed the 5-year OS.^[@B19],[@B27],[@B28],[@B31],[@B32],[@B35]^ Only two studies^[@B31],[@B32]^ calculated HRs. All others included *P* values and the number of events. No significant differences in 5-year DFS and OS were found between the two groups (HR = 0.01; 95% CI, −0.10, 0.11; *P* = .91; and HR = −0.02; 95% CI, −0.14, 0.10; *P* = .73, respectively) ([Fig. 1a](#f1){ref-type="fig"}).

![Forest plot and meta-analysis of prognostic results: **(a)** 5-year disease-free survival (DFS) and overall survival (OS) and **(b)** recurrence rate. CI, confidence interval; IV, inverse variance method; lap, laparoscopic; M-H, Mantel--Haenszel method; SE, standard error; CI = confidence interval).](fig-1){#f1}

Thirteen studies^[@B18],[@B24],[@B30],[@B32],[@B33],[@B35]^ assessed RR among 2274 patients. During the follow-up period, the RR did not differ between the LRH and ARH groups under the balanced prognostic factors (8.77% versus 11.93%; OR = 0.82; 95% CI, 0.61, 1.11; *P* = .20) ([Fig. 1b](#f1){ref-type="fig"}).

Secondary outcomes {#s009}
------------------

### Safety parameters {#s010}

LRH was safer. The total effects of intraoperative intestine or urinary injuries and intraoperative, perioperative, or postoperative complications showed the following result: 12.41% versus 15.15%; OR = 0.82; 95% CI, 0.71, 0.96; *P* = .01. Also, the total effect of postoperative bowel or bladder recovery days showed ARH had a longer recovery time (WMD = −1.08 days; 95% CI, −1.67, 0.50; *P* = .0003).

Seventeen studies^[@B15],[@B22],[@B23],[@B25],[@B31],[@B32],[@B35],[@B36]^ including a total of 2365 patients described intraoperative bowel or urinary injury and showed some difference between the LRH group and the ARH group, but the difference was not significant (4.99% versus 3.12%; OR = 1.50; 95% CI, 0.99, 2.26; *P* = .06). Other intraoperative and postoperative complication rates were available for 10 studies^[@B16],[@B17],[@B20],[@B23],[@B27],[@B28],[@B31],[@B36]^ and 18 studies,^[@B15],[@B23],[@B27],[@B35],[@B36]^ respectively. Intraoperative complication rates, which mainly were due to vessel and nerve injuries, did not significantly differ between the LRH and ARH groups (3.44% versus 2.27%; OR = 1.48; 95% CI, 0.75, 2.91; *P* = .25). Postoperative complication rates were significantly higher in the ARH group than in the LRH group (25.09% versus 31.41%; OR = 0.74; 95% CI, 0.61, 0.90; *P* = .002). Four studies^[@B19],[@B27],[@B28],[@B35]^ reporting perioperative complication rates showed lower rates in the LAH group compared with the ARH group (8.57% versus 14.05%; OR = 0.56; 95% CI, 0.36, 0.90; *P* = .02) ([Fig. 2](#f2){ref-type="fig"}).

![Forest plot and meta-analysis of safety parameters: intraoperative (Intra-op), postoperative (post-op), and perioperative (peri-op) complications and intraoperative urinary-intestine injury. AE, adverse event; CI, confidence interval; lap, laparoscopic; M-H, Mantel--Haenszel method.](fig-2){#f2}

Three studies^[@B20],[@B24],[@B37]^ and three studies,^[@B24],[@B26],[@B37]^ respectively, reported the postoperative bladder and anorectal function recovery time. No significant differences were found for the recovery of bladder function (WMD = −2.48 days; 95% CI, −5.16, 0.19; *P* = .07), but a significant difference was found in the number of days for anorectal function recovery (WMD = −0.80 days; 95% CI, −1.16, −0.44; *P* \< .00001) ([Table 2](#T2){ref-type="table"}).

### Efficiency parameters {#s011}

Efficiency parameters included pelvic and para-aortic lymph nodes removed and showed no difference (WMD = −1.48; 95% CI, −3.73, 0.77; *P* = .20). Sixteen studies^[@B16],[@B18],[@B19],[@B21],[@B30],[@B36]^ reported the number of pelvic lymph nodes removed, and two studies^[@B24],[@B26]^ reported the number of para-aortic lymph nodes removed; no significant differences were found between the two groups for either type of node (WMD = −1.44; 95% CI, −4.14, 1.27; *P* = .30 and WMD = −1.79; 95% CI, −6.39, 2.82; *P* = .45, respectively) ([Table 2](#T2){ref-type="table"}).

### Other parameters {#s012}

In total, 17 studies^[@B15],[@B16],[@B18],[@B19],[@B22],[@B30],[@B35],[@B36]^ including 2224 cases reported the operative time, and 16 studies^[@B16],[@B18],[@B19],[@B22],[@B30],[@B35],[@B36]^ including approximately 2491 patients reported the LOS. The laparoscopic group required a significantly longer operation time (WMD = 18.76 minutes; 95% CI, 2.13, 35.39; *P* = .03). The abdominal group had a significantly longer LOS (WMD = −4.36 days; 95% CI, −5.38, −3.34; *P* \< .00001) ([Table 2](#T2){ref-type="table"}).

Seventeen studies^[@B16],[@B22],[@B30],[@B35],[@B36]^ reported EBL for 2570 patients and showed significantly greater EBL among the ARH group (WMD = −193.61 mL; 95% CI, −236.80, −150.43; *P* \< .00001) ([Table 2](#T2){ref-type="table"}).

Sensitivity analysis and publication bias {#s013}
-----------------------------------------

Using the modified Newcastle--Ottawa Scale to assess the quality, 1 RCT^[@B15]^ and 13 retrospective studies^[@B15],[@B22],[@B23],[@B26],[@B28],[@B35]^ that scored six or more stars were included in a sensitivity analysis ([Table 3](#T3){ref-type="table"}). No change occurred in the significance of any of the outcomes except for the perioperative complication rates, which did not significantly differ between the LRH and ARH groups (OR = 0.66; 95% CI, 0.32, 1.73; *P* = .22). The degree of between-study heterogeneity decreased slightly for DFS, OS, RR, intraoperative bowel and urinary injury, and the perioperative complication rate, although the between-study heterogeneity remained statistically significant for the postoperative complication rate, operative time, EBL, LOS, and number of lymph nodes removed. One study was included for the para-aortic lymph node, and no study included the bladder recovery day in the sensitivity analysis.

###### 

[Sensitivity Analysis Comparison of Laparoscopic Radical Hysterectomy and Abdominal Radical Hysterectomy]{.smallcaps}

                                                          *Number of patients*                                       *Study heterogeneity*                      
  -------------------------------------------------- ---- ---------------------- ------ ---------------------------- ----------------------- -------- ---- ---- --------------
  Primary outcomes                                                                                                                                              
   5-year DFS^[b](#tf8){ref-type="table-fn"}^        6    608                    686    0.02 (−0.11, 0.15)           .77                     4.00     5    0    .55
   5-year OS^[b](#tf8){ref-type="table-fn"}^         4    503                    576    −0.01 (−0.15, 0.14)          .93                     2.81     3    0    .42
   Recurrence rate^[b](#tf8){ref-type="table-fn"}^   7    613                    895    0.80 (0.53, 1.22)            .30                     2.14     6    0    .91
  Secondary outcomes                                                                                                                                            
   Intraoperative bowel-urinary injury               13   802                    889    1.49 (0.93, 2.37)            .10                     5.77     12   0    .93
   Perioperative complication                        2    146                    255    0.66 (0.32, 1.73)            .26                     1.52     1    34   .22
   Postoperative complication                        12   781                    1070   0.78 (0.63, 0.97)            **.02**                 37.14    11   70   **.0001**
   Intraoperative complication                       4    159                    175    0.79 (0.28, 2.20)            .65                     3.04     3    1    .38
   Anorectal recovery (days)                         2    73                     78     −0.65 (−0.93, −0.36)         **\<.00001**            0.62     1    0    .43
   Operation time (minutes)                          12   656                    1053   20.89 (0.53, 41.25)          **.04**                 154.99   11   93   **\<.00001**
   Length of stay (days)                             11   757                    1056   −3.98 (−4.99, −2.98)         **\<.00001**            73.90    10   86   **\<.00001**
   Blood loss (mL)                                   12   792                    1100   −179.84 (−225.40, −134.28)   **\<.00001**            50.34    11   78   **\<.00001**
   Pelvic LNs removed                                10   494                    793    −0.99 (−6.07, 4.10)          .70                     148.87   9    94   **\<.00001**

Statistically significant results are shown in bold.

Prognostic factors were not significantly different.

ARH, abdominal radical hysterectomy; CI, confidence interval; *df*, degrees of freedom; DFS, disease-free survival; LN, lymph node; LRH, laparoscopic radical hysterectomy; OS, overall survival; WMD/OR, weighted mean difference/odds ratio.

The funnel plot of the studies that reported intra-, peri-, and postoperative complications showed that almost all studies lie inside the 95% CI and have an even distribution around the vertical axis, indicating that no obvious publication bias exists.

Discussion {#s014}
==========

LRH has become increasingly common in clinical practice, mainly because the procedure is thought to be safe and efficient, potentially reducing postoperative morbidity compared with that of conventional radical hysterectomy. To examine whether this viewpoint is well founded, a systematic review of the literature was performed to compare the prognostic and safety results of LRH and ARH. This meta-analysis of 1 RCT and 21 retrospective studies including 2922 patients showed that LRH was safe and had significantly fewer peri- and postoperative complications, shorter bowel recovery time, reduced intraoperative blood loss, and shorter hospital stay than ARH, even though the operative time was increased. The rates of intraoperative bladder and intestine injuries were increased but were not significantly different. No significant differences were found in 5-year DFS and OS, as well as RR, during follow-up or in the numbers of pelvic or para-aortic lymph nodes removed.

These conclusions are consistent with at least one study that performed a systematic analysis of one RCT of 13 women, of whom 7 had a laparoscopically assisted radical hysterectomy and 6 had ARH.^[@B8]^

The LRH and ARH groups were not significantly different in terms of survival, and the safety of these approaches was evident. Data included the 5-year DFS and OS, as well as RR, with balanced prognostic factors including lymph node metastasis, Stage IIB or above, non--squamous cancer histology, Grade G3, lymphovascular space invasion, tumor size ≥4 cm, positive parametrial margin rate, and positive vaginal margin positive rate, which demonstrated the possibility of recurrence and postoperative adjuvant therapy. The factors assessed were identical, and the surgical specimens removed were similar.

The finding that LRH and ARH are associated with similar survival indirectly reflects our finding that these approaches have similar safety. The total complication rate was higher in ARH than LRH. These two approaches were associated with similar rates of intraoperative complications, including vessel injury, nerve injury, and thromboembolism. Greater risks of intraoperative bladder and intestine injury were observed in the LRH group, although LRH had longer operative time. Intraoperative urinary injury may be related to several other factors, including surgeons\' experience and familiarity with using the laparoscopic system for malignant pelvic conditions. Different postoperative complications such as urinary retention, urinary incontinence, bladder sensation loss, fistula, bowel obstruction, lymphocyst formation, wound dehiscence, hypertrophic scar, and infectious complications were found among the pooled studies. Additionally, LRH is thought to be associated with fewer days of postoperative anorectal function recovery, supporting the use of the minimally invasive laparoscopic approach. In contrast, the postoperative days of catheterization did not significantly differ between these two groups. Conversely, LRH was associated with less blood loss, a lower transfusion rate, and a shorter hospital stay, supporting the use of the minimally invasive LRH approach to treat cervical cancer.

We did not systematically analyze the postoperative pain score. Postoperative pain was assessed during the patients\' normal postoperative care and was measured using a 10-point visual analog scale. Three studies reported lower visual analog scale pain scores and less opiate analgesic use in the LRH group than in the ARH group.^[@B15],[@B37],[@B38]^ Moreover, quality of life was improved in the LRH group.^[@B37]^ The less invasive nature, minimal impairment, and cosmetic satisfaction were the main reasons for the improved quality of life. Psychological fear may increase visual analog scale scores and requests for additional analgesics, as the ARH approach requires a large incision and anesthesia.

For an oncology surgeon, the learning curve for LRH for malignant neoplasm is steeper, so this procedure should be performed by skilled specialists who pay attention to the patients\' set-up, port placement, and surgical steps, as these differ from conventional ARH but are required for patient safety and satisfaction (little scarring, fewer hemorrhagic complications, and shorter hospital stays). From this perspective, our findings must be interpreted cautiously because the ability to generalize these results to less experienced surgeons is not guaranteed.

Sensitivity analysis of RCTs and high-quality studies that attained scores of six stars and above was performed to assess the impact of study quality. Outcomes showed that the majority of results were similar and did not significantly differ between the two groups. However, for perioperative complication rates, the sensitivity analysis showed different results. Additional RCTs should be performed with more complete data to allay ethical concerns and patient expectations by providing more definitive conclusions.

This systematic analysis and meta-analysis of LRH and ARH evaluated the safety, efficiency, and clinical complications of the two approaches. Our study had some limitations and bias. The main limitation was that only one RCT was included and that the other included studies were retrospective or prospective. One retrospective abstract were included despite lacking complete data. Additionally, a random sequence could not be obtained, which might have introduced bias. Without the full articles, the possibility of selection and data bias increases because of the lack of information for each end point. Furthermore, for DFS and OS, only two studies included HRs, which accurately depict the survival rate, but all included studies had survival curves from which HRs could be calculated. Additionally, the follow-up period was generally short. Thus, long-term outcomes for cervical cancer safety remain unknown. Future systematic reviews should separately evaluate different indications when adequate data are available.

RCTs are controversial because of ethical concerns; thus it is difficult to compare these surgical techniques. This meta-analysis highlights the comparisons and was conducted at an appropriate time, when enough data have accumulated for meta-analytical methods. Additionally, a non-English study^[@B37]^ and an article published by Chinese authors^[@B25]^ were included to minimize publication bias. All RCT and retrospective articles were reviewed and analyzed. Multiple strategies were identified to control the bias, to evaluate the methodological quality of the studies using strict criteria, and to minimize the heterogeneity with sensitivity analysis. Hence, we provide the most up-to-date information in this area of research.

In conclusion, this article showed that LRH has prognostic results, including DFS, OS, and RR, similar to those of ARH and has fewer complications. The numbers of pelvic and para-aortic lymph nodes removed are identical. LRH shows the nature of minimally invasive nature and little impairment, although LRH is associated with longer operative time and increased risks of intraoperative urinary or intestine injuries. However, the limitations of the included studies prevent us from making more accurate conclusions, and these results must be confirmed and updated by future well-designed RCTs with extensive follow-up periods.

Acknowledgments {#s015}
===============

We thank other members of the Department of Gynecologic Oncology at Sun Yat-sen University Cancer Center who did not contribute directly to this review but gave valuable advice throughout the study.

Disclosure Statement {#s016}
====================

No competing financial interests exist.

J.L. and T.C. are responsible for study concept and design. T.C. and Q.H. are responsible for acquisition of data. T.C., Y.F., and Q.H. are responsible for analysis and interpretation of data. T.C., Y.F., and J.L. are responsible for drafting of the manuscript. T.W. and Q.H. are responsible for critical revision of the manuscript for important intellectual content. T.C., Y.F., and T.W. are responsible for statistical analysis. T.C., Y.F., and Q.H. are responsible for administrative, technical, or material support. J.L. had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis so is the guarantor of the content.

[^1]: The first two authors contributed equally to this study.
